NIPPON-KINZOKU
23.7.2024 10:02:34 CEST | Business Wire | Press release
NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) announces that it has named and registered the trademark "Fine Profile" for its cold profile rolled products, which can be used for various metals from ferrous to nonferrous, by combining its proprietary cold rolling technology and specialized equipment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723992481/en/
Fine Profile is a generic term for products made by continuously processing ferrous and nonferrous metals into irregularly shaped cross sections with different thicknesses in the width direction using our unique rolling technology. It contributes to customers' process reduction, environmental improvement, manufacturing cost reduction, and yield improvement as an alternative to various processes such as cutting and grinding. (Graphic: Business Wire)
Fine Profile is our original new product that contributes to customers' manufacturing cost reduction and yield improvement as an alternative to various machining processes such as cutting and grinding, and we aim to expand sales of this product in the future.
Features
-
Cost reduction of metal processing, resource saving, energy saving
Use of a deformed cross-sectional shape contributes to reduce machining processes and waste. -
Stabilization of quality
Continuous rolling from coil provides stable supply of high quality products. -
Roll forming on metal surfaces
By rolling the uneven pattern on the roll surface, it is possible to process various designs and functions such as unique designs, oil grooves, gloss prevention, identification grooves, etc. -
Various delivery forms
We can deliver products in a variety of forms, such as record rolls, oscillate rolls, fixed-length products, and secondary processing, etc. according to customer needs. -
Shorter development period
Roll design using CAE analysis contributes to reduction of customers' development cost and time.
Metal types
Nonferrous metals: oxygen-free copper, copper alloys, aluminum alloys, pure titanium, titanium alloys, pure nickel, magnesium alloys, etc.
Stainless steel: SUS304 (L), SUS316 (L), SUS430, SUS420J2, SUS440C, etc.
Carbon steel: SS400, SPCD, SPCC, SPHC, SECC, etc.
Special steel: SCM415, SUJ2, S10C, S45C, S65C, SAE1070, SK75, SK95, SKS81, 1LSSP, etc.
* Please inquire separately for specifications other than those listed above.
Application examples
Fine Profile is developed and manufactured by our rolling technologies and co-creation with our customers that require stable quality and reliability in various applications.
- Automotive applications (Automotive drive parts, Bearing components, Vane pump parts, Engine parts, etc.)
- Electrical and electronic parts applications (Connector parts, Secondary battery terminals, Heat spreaders, Bus bars, etc.)
- Building material applications (Grating components, Braille studs, Screen components, Special fasteners, etc.)
About NIPPON KINZOKU Group
Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723992481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 13:00:00 CEST | Press release
Largest fundraise in the firm’s history brings total capital raised to more than $75 billion Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management23.7.2026 09:00:00 CEST | Press release
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/ Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independently across different countries, meaning employees were dealing with a patchwork of different tools and manual offline processes. As part of its focus on operational excellence, Evot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom